EU Faces Scrutiny Over Biotech Competitiveness Measures

The European Union's approach to strengthening its biotechnology sector is under intense discussion as policymakers, industry leaders, and researchers assess proposed legislative reforms aimed at boosting innovation and market competitiveness. Recent conversations during the Tagesspiegel Health4EU forum highlighted both progress and challenges as the EU moves forward with its Biotech Act, an initiative designed to accelerate the development and commercialization of biotechnological products and therapies.

The Biotech Act, introduced as a draft by the European Commission in December 2025, seeks to provide a comprehensive legal framework to better support the biotechnology industry across the continent. The primary goal is to enhance Europe's attractiveness for investment and encourage the growth of advanced therapies and innovative health solutions. While stakeholders generally regard the Act as a positive step, many believe it must be more ambitious to effectively address the needs of the sector and establish the EU as a global leader in biotechnology.

One of the key issues debated at the forum was the current state of investment in European biotechnology. EU officials and industry representatives acknowledged that the sector faces significant hurdles, particularly the high costs and risks associated with biotech research and development. Although financing instruments from the EU and the European Investment Bank are already in place to offer low-risk loans to companies, the uptake of such support remains limited. This reluctance is often attributed to the existing disconnect between research outputs and market readiness, which can deter companies from committing resources to new biotechnological ventures.

Experts emphasized the importance of closing the gap between scientific research and commercial application. One suggested solution is to adopt model-based research approaches, which prioritize computer-aided and mathematical modeling over traditional physical prototyping. By leveraging these advanced techniques, biotech firms can potentially reduce both the cost and time required to bring new products to market, making the sector more attractive for investment and innovation.

The European Union's strengths were also highlighted during the discussions. The region boasts a highly skilled scientific workforce and a robust research infrastructure, which are seen as essential assets for fostering innovation and maintaining competitiveness. Furthermore, the EU's legal framework, which recognizes access to healthcare as a fundamental right, offers companies planning certainty and a large, unified market for new health products and therapies. These advantages contribute to Europe's position as a significant player in the global biotech industry.

Despite these strengths, concerns persist that the EU may not be moving quickly enough to secure its leadership in biotechnology. Stakeholders cautioned that the region must act decisively to avoid falling behind other major markets, particularly amid intensifying global competition and rapidly evolving biotechnology landscapes in countries such as the United States and China. There is a consensus that timely implementation of the Biotech Act and continued investment in research and development are critical for ensuring Europe's long-term success in this strategic sector.

The discussions also touched on the global context of biotechnology policy, referencing recent legislative actions in other regions. For example, the United States passed the Biosecure Act in 2025 as a response to growing competition from China, highlighting the geopolitical dimensions of biotech innovation and the increasing importance of strategic autonomy in health technologies.

As the legislative process for the EU Biotech Act continues, various interest groups and policymakers are actively engaged in revising and refining the proposal. The outcome of these deliberations will shape the future trajectory of the European biotechnology sector, with significant implications for health innovation, economic growth, and the region's ability to respond to emerging health challenges.